Denali Therapeutics Inc. Common Stock (DNLI)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Denali Therapeutics Inc. Common Stock (DNLI)
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Key Insights
Critical company metrics and information
Share Price
$24.89Market Cap
$3.58 BillionTotal Outstanding Shares
143.92 Million SharesTotal Employees
390Dividend
No dividendIPO Date
December 8, 2017SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.denalitherapeutics.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow | $-57.38 Million |
Net Cash Flow From Financing Activities | $493.18 Million |
Net Cash Flow From Operating Activities | $-362.64 Million |
Net Cash Flow From Financing Activities, Continuing | $493.18 Million |
Net Cash Flow From Investing Activities, Continuing | $-187.92 Million |
Net Cash Flow From Investing Activities | $-187.92 Million |
Net Cash Flow From Operating Activities, Continuing | $-362.64 Million |
Net Cash Flow, Continuing | $-57.38 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Benefits Costs and Expenses | $322.56 Million |
Net Income/Loss Attributable To Parent | $-427.49 Million |
Income/Loss From Continuing Operations Before Tax | $-308.02 Million |
Revenues | $14.54 Million |
Income/Loss From Continuing Operations After Tax | $-427.49 Million |
Basic Average Shares | $162.88 Million |
Basic Earnings Per Share | $2.76 |
Research and Development | $404.46 Million |
Costs And Expenses | $504.60 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Other Operating Expenses | $100.15 Million |
Diluted Earnings Per Share | $2.76 |
Net Income/Loss | $-427.49 Million |
Diluted Average Shares | $162.88 Million |
Operating Expenses | $504.60 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-427.49 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Operating Income/Loss | $-490.07 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities And Equity | $1.45 Billion |
Fixed Assets | $50.82 Million |
Other Non-current Assets | $534.35 Million |
Liabilities | $135.52 Million |
Equity Attributable To Parent | $1.32 Billion |
Noncurrent Liabilities | $48.42 Million |
Equity | $1.32 Billion |
Wages | $14.87 Million |
Assets | $1.45 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Other Current Liabilities | $62.63 Million |
Noncurrent Assets | $585.17 Million |
Current Assets | $868.84 Million |
Accounts Payable | $9.59 Million |
Current Liabilities | $87.09 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.